We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide.
- Authors
Htet, T. D.; Eisman, J. A.; Elder, G. J.; Center, J. R.
- Abstract
Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.
- Subjects
TERIPARATIDE; AUTOIMMUNE diseases; OSTEOPOROSIS; SOFT tissue tumors; WHITE people; SEVERITY of illness index; SYMPTOMS; THERAPEUTICS
- Publication
Osteoporosis International, 2018, Vol 29, Issue 2, p517
- ISSN
0937-941X
- Publication type
Article
- DOI
10.1007/s00198-017-4330-7